References

1. **National Committee for Clinical Laboratory Standards:** Antimicrobial susceptibility testing/SC3. 3rd ed. Villanova, PA, NCCLS, 1990.
2. **Crombach, W. H. J., Dijkshoorn, L., van Noort-Klaasen, M., Niesen, J., van Knippenberg-Gordebeke, G.:** Control of an epidemic spread of multiresistant strain of *Acinetobacter calcoaceticus* in a hospital. *Intensive Care Med.* 15 (1989) 166–170.
3. **Vila, J., Almela, M., Jimenez de Anta, M. T.:** Laboratory investigation of hospital outbreak caused by two different multiresistant *Acinetobacter calcoaceticus* var. *anitratus* in an intensive care unit. *J. Clin. Microbiol.* 27 (1989) 1086–1089.
4. **Scerpella, E. G., Wanger, A. R., Anderlini, P., Urteaga, J., Marani, S. A., Ericsson, C. D.:** A multi-hospital nosocomial outbreak with multiresistant *Acinetobacter calcoaceticus*: results of the epidemiologic and molecular investigations. 33rd ICAAC, New Orleans, USA, 1993, 512.
5. **Allen, D. M., Hartman, B. J.:** *Acinetobacter* species. In: *Mandell, G. L., Douglas, R. G., Bennett, J. E.* (eds.): *Manual of clinical microbiology*, 3rd ed. Churchill Livingstone, New York 1990, pp. 1696–1700.
6. **Pickett, M. J., Hollis, D. G., Bottone, E. J.:** Miscellaneous gram-negative bacteria. In: *Balows, A., Hausler, W. J., Herrman, K. L., Tenenberg, H. D., Shadomy, H. J.* (eds.): *Manual of clinical microbiology*, 5th ed. American Society for Microbiology, Washington 1991, pp. 410–428.
7. **Bouvet, P. J., Grimont, P. A.:** Taxonomy of the genus *Acinetobacter* with the recognition of *Acinetobacter baumannii* sp. nov., *Acinetobacter haemolyticus* sp. nov., *Acinetobacter johnsonii* sp. nov., and *Acinetobacter junii* sp. nov., and emended description of *Acinetobacter calcoaceticus* and *Acinetobacter lwoffii*. *Int. J. Syst. Bacteriol.* 36 (1986) 228–240.
8. **Traub, W. H., Spohr, M.:** Antimicrobial drug susceptibility of clinical isolates of *Acinetobacter* species (*A. baumannii*, *A. haemolyticus*, genospecies 3, and genospecies 6). *Antimicrob. Agents Chemother.* 33 (1989) 1617–1619.
9. **Seifert, H., Baginski, R., Schulze, A., Pulverer, G.:** Antimicrobial susceptibility of *Acinetobacter* species. *Antimicrob. Agents Chemother.* 37 (1993) 750–753.
10. **Von Graevenitz, A.:** Endocarditis due to nonfermentative gram-negative rods. An updated review. *Eur. Heart J.* 8 (1987) 331–334.
11. **Gradon, J. D., Chapnick, E. K., Lutwick, L. I.:** Infective endocarditis of a native valve due to *Acinetobacter*: Case report and review. *Clin. Infect. Dis.* 14 (1992) 1145–1148.
12. **Katz, N. M., Blackstone, E. H., Kirklin, J. W.:** Late survival and symptoms after repair of tetralogy of Fallot. *Circulation* 65 (1982) 403–410.
13. **Hallali, P., Davido, A., Corone, P.:** Tetralogy of Fallot: 20 years' experience concerning 144 cases. *Arch. Mal. Coeur Vaiss.* 82 (1989) 683–688.
14. **Linde, L. M., Heins, H. L.:** Bacterial endocarditis following surgery for congenital heart disease. *N. Engl. J. Med.* 263 (1960) 63–69.
15. **Amoury, R. A., Bowman, F. O., Malm, J. R.:** Endocarditis associated with intracardiac prostheses. *J. Thorac. Cardiovasc. Surg.* 51 (1966) 36–47.
16. **Vaseenon, T., Park, M. K., Diehl, A. M.:** Recurrence of shunt induced by bacterial endocarditis following correction of tetralogy of Fallot. *Am. J. Dis. Child* 131 (1977) 1295–1296.
17. **Smolinski, A., Ziskind, Z., Ruvolo, G., Goor, D. A.:** Staged surgical treatment of early bacterial endocarditis after surgical repair of tetralogy of Fallot and discrete subaortic stenosis: report of a case. *J. Thorac. Cardiovasc. Surg.* 90 (1985) 788–789.

Errata

W. Marget: Re: Oral Administration of a Certain Strain of Live *Escherichia coli* for Intestinal Disorders? (*Infection* 23 [1995] 51–54), Concluding Statement, *Infection* 23 (1995) 188, reference 8: the commentary by *Knothe* referred to as “in press” is in the present issue with the title: The Story of Live Human Intestinal Bacteria Administered Orally as a Remedy.

S. G. Jenkins, J. W. Lewis: In der deutschen Zusammenfassung von “Synergistic Interaction between Ofloxacin and Cefotaxime

against Common Clinical Pathogens” *Infection* 23 (1995) 161, Zeile 15–17, muß es heißen: Ein Synergismus oder partieller Synergismus zwischen CTX, DES und OFL fand sich bei 89 von 110 geprüften Isolaten (81%). Nach Zeile 27 fehlt aus dem englischen Text eine Passage und wird hiermit ergänzt: Synergismus oder partieller Synergismus war gegen 81 (91%) feststellbar. Eine geringere synergistische Aktivität fand sich hingegen bei Erregern der *Bacteroides-fragilis*-Gruppe. Synergismus oder partieller Synergismus fand sich nur bei 27 (57%) von 48 geprüften Isolaten.